Oncological treatment in Brazil: a gender and region are associated to starting the therapeutics
Introduction: Malignant neoplasms are a major public health problem, being the second leading cause of death in the world. In 2012, the Ministry of Health (BR) instituted Law No. 12,732, which grants cancer patients the right to obtain, from the anatomopathological diagnosis, access to the first tre...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia
2021-10-01
|
| Series: | Brazilian Journal of Oncology |
| Subjects: | |
| Online Access: | http://www.brazilianjournalofoncology.com.br/details/142/en-US/oncological-treatment-in-brazil--a-gender-and-region-are-associated-to-starting-the-therapeutics |
| _version_ | 1797673890264121344 |
|---|---|
| author | Isabelle Maria dos Anjos Chaves Vitória Alice Alves de Oliveira Davi Neri Araujo Fernanda Freitas Lemos Lopes Artur Trancoso Lopo de Queiroz Maisa Almeida Silva Alexandre Souza Queiroz Lygia Accioly Tinoco Kiyoshi Ferreira Fukutani |
| author_facet | Isabelle Maria dos Anjos Chaves Vitória Alice Alves de Oliveira Davi Neri Araujo Fernanda Freitas Lemos Lopes Artur Trancoso Lopo de Queiroz Maisa Almeida Silva Alexandre Souza Queiroz Lygia Accioly Tinoco Kiyoshi Ferreira Fukutani |
| author_sort | Isabelle Maria dos Anjos Chaves |
| collection | DOAJ |
| description | Introduction: Malignant neoplasms are a major public health problem, being the second leading cause of death in the world. In 2012, the Ministry of Health (BR) instituted Law No. 12,732, which grants cancer patients the right to obtain, from the anatomopathological diagnosis, access to the first treatment in the Brazilian Healthcare System - Sistema Único de Saúde (SUS), within up to sixty days. The change in the patient’s prognosis is the aim of this program.
Objective: To evaluate the panorama of the time to start cancer therapy in Brazil.
Methods: This is a cross-sectional and analytical study on the time for the establishment of the beginning of cancer treatment in Brazil, in the period from 2013 to 2019. The data were extracted from the PANEL-Oncology of the informatics department of Unified Health System. Chi-square and Fisher’s exact tests were used to analyze proportions and risk ratios, respectively.
Results: The percentage of malignant neoplasms that had the longest delay in starting therapy (>60 days) in the country were prostate (59.6%) and cervix (50.9%). As for sex, the delay was present in 36.9% of men and 33.3% of women (p<0.05). Differences in the rates of cancers with and without delay for the institution of treatment are also evident in the Brazilian macroregions (p<0.05). Assessing the odds ratio for delayed cancer treatment, the male gender is shown to be a risk factor (p<0.05) in all regions, except in the North of the country. The risk for delayed treatment differs depending on the type of cancer.
Conclusion: Cancers that have a longer delay in starting therapy are those that have health policies aimed at their screening. |
| first_indexed | 2024-03-11T21:51:56Z |
| format | Article |
| id | doaj.art-e71f9fb2612b4e0b8b32141bdf61bef4 |
| institution | Directory Open Access Journal |
| issn | 2526-8732 |
| language | English |
| last_indexed | 2024-03-11T21:51:56Z |
| publishDate | 2021-10-01 |
| publisher | Sociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de Radioterapia |
| record_format | Article |
| series | Brazilian Journal of Oncology |
| spelling | doaj.art-e71f9fb2612b4e0b8b32141bdf61bef42023-09-26T09:00:16ZengSociedade Brasileira de Oncologia Clínica, Sociedade Brasileira de Cirurgia Clínica and Sociedade Brasileira de RadioterapiaBrazilian Journal of Oncology2526-87322021-10-01170010.5935/2526-8732.20200045Oncological treatment in Brazil: a gender and region are associated to starting the therapeuticsIsabelle Maria dos Anjos Chaves0https://orcid.org/0000-0002-7009-0852Vitória Alice Alves de Oliveira1https://orcid.org/0000-0002-3368-3595Davi Neri Araujo2https://orcid.org/0000-0002-3089-8312Fernanda Freitas Lemos Lopes3https://orcid.org/0000-0001-8801-1799Artur Trancoso Lopo de Queiroz4https://orcid.org/0000-0003-4908-9993Maisa Almeida Silva5https://orcid.org/0000-0002-7104-7493Alexandre Souza Queiroz6https://orcid.org/0000-0002-5405-5627Lygia Accioly Tinoco7Kiyoshi Ferreira Fukutani8https://orcid.org/0000-0003-2223-0918Centro Universitário FTC, Curso de Medicina, Salvador, Bahia, BrazilCentro Universitário FTC, Curso de Medicina, Salvador, Bahia, BrazilUniversidade Federal da Bahia, Curso de Medicina, Salvador, Bahia, BrazilCentro Universitário FTC, Curso de Medicina, Salvador, Bahia, BrazilFundação Oswaldo Cruz, Instituto Gonçalo Moniz, Salvador, Bahia, BrazilFaculdade Bahiana para o Desenvolvimento da Ciência, Curso de Fisioterapia, Salvador, Bahia, BrazilFundação Oswaldo Cruz, Instituto Gonçalo Moniz, Salvador, Bahia, BrazilHospital São Rafael, Departamento de Oncologia, Salvador, Bahia, BrazilCentro Universitário FTC, Curso de Medicina, Salvador, Bahia, BrazilIntroduction: Malignant neoplasms are a major public health problem, being the second leading cause of death in the world. In 2012, the Ministry of Health (BR) instituted Law No. 12,732, which grants cancer patients the right to obtain, from the anatomopathological diagnosis, access to the first treatment in the Brazilian Healthcare System - Sistema Único de Saúde (SUS), within up to sixty days. The change in the patient’s prognosis is the aim of this program. Objective: To evaluate the panorama of the time to start cancer therapy in Brazil. Methods: This is a cross-sectional and analytical study on the time for the establishment of the beginning of cancer treatment in Brazil, in the period from 2013 to 2019. The data were extracted from the PANEL-Oncology of the informatics department of Unified Health System. Chi-square and Fisher’s exact tests were used to analyze proportions and risk ratios, respectively. Results: The percentage of malignant neoplasms that had the longest delay in starting therapy (>60 days) in the country were prostate (59.6%) and cervix (50.9%). As for sex, the delay was present in 36.9% of men and 33.3% of women (p<0.05). Differences in the rates of cancers with and without delay for the institution of treatment are also evident in the Brazilian macroregions (p<0.05). Assessing the odds ratio for delayed cancer treatment, the male gender is shown to be a risk factor (p<0.05) in all regions, except in the North of the country. The risk for delayed treatment differs depending on the type of cancer. Conclusion: Cancers that have a longer delay in starting therapy are those that have health policies aimed at their screening.http://www.brazilianjournalofoncology.com.br/details/142/en-US/oncological-treatment-in-brazil--a-gender-and-region-are-associated-to-starting-the-therapeuticsoncologytherapeuticsrisk factors |
| spellingShingle | Isabelle Maria dos Anjos Chaves Vitória Alice Alves de Oliveira Davi Neri Araujo Fernanda Freitas Lemos Lopes Artur Trancoso Lopo de Queiroz Maisa Almeida Silva Alexandre Souza Queiroz Lygia Accioly Tinoco Kiyoshi Ferreira Fukutani Oncological treatment in Brazil: a gender and region are associated to starting the therapeutics Brazilian Journal of Oncology oncology therapeutics risk factors |
| title | Oncological treatment in Brazil: a gender and region are associated to starting the therapeutics |
| title_full | Oncological treatment in Brazil: a gender and region are associated to starting the therapeutics |
| title_fullStr | Oncological treatment in Brazil: a gender and region are associated to starting the therapeutics |
| title_full_unstemmed | Oncological treatment in Brazil: a gender and region are associated to starting the therapeutics |
| title_short | Oncological treatment in Brazil: a gender and region are associated to starting the therapeutics |
| title_sort | oncological treatment in brazil a gender and region are associated to starting the therapeutics |
| topic | oncology therapeutics risk factors |
| url | http://www.brazilianjournalofoncology.com.br/details/142/en-US/oncological-treatment-in-brazil--a-gender-and-region-are-associated-to-starting-the-therapeutics |
| work_keys_str_mv | AT isabellemariadosanjoschaves oncologicaltreatmentinbrazilagenderandregionareassociatedtostartingthetherapeutics AT vitoriaalicealvesdeoliveira oncologicaltreatmentinbrazilagenderandregionareassociatedtostartingthetherapeutics AT davineriaraujo oncologicaltreatmentinbrazilagenderandregionareassociatedtostartingthetherapeutics AT fernandafreitaslemoslopes oncologicaltreatmentinbrazilagenderandregionareassociatedtostartingthetherapeutics AT arturtrancosolopodequeiroz oncologicaltreatmentinbrazilagenderandregionareassociatedtostartingthetherapeutics AT maisaalmeidasilva oncologicaltreatmentinbrazilagenderandregionareassociatedtostartingthetherapeutics AT alexandresouzaqueiroz oncologicaltreatmentinbrazilagenderandregionareassociatedtostartingthetherapeutics AT lygiaacciolytinoco oncologicaltreatmentinbrazilagenderandregionareassociatedtostartingthetherapeutics AT kiyoshiferreirafukutani oncologicaltreatmentinbrazilagenderandregionareassociatedtostartingthetherapeutics |